News
Eli Lilly's (LLY) experimental obesity drug, eloralintide, shows up to 11% weight loss in 12 weeks with minimal side effects in early-stage trial. Read more here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback